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ABSTRACT 
Syrbactins belong to a recently emerged class of bacterial natural product inhibitors that 
irreversibly inhibit the proteasome of eukaryotes by a novel mechanism. The total syntheses of 
the syrbactin molecules syringolin A, syringolin B, and glidobactin A have been achieved which 
enabled the preparation of syrbactin-inspired derivatives, such as the syringolin A/glidobactin A 
hybrid molecule SylA-GlbA. To determine the potency of SylA-GlbA, we employed both in 
vitro and cell culture-based proteasome assays that measure the sub-catalytic chymotrypsin-like 
(CT-L), trypsin-like (T-L), and caspase-like (C-L) activities. We further studied the inhibitory 
effects of SylA-GlbA on tumor cell growth, using a panel of multiple myeloma, neuroblastoma, 
and ovarian cancer cell lines and showed that SylA-GlbA strongly blocks the activity of NF-κB. 
To gain more insights into the structure-activity relationship, we co-crystallized the SylA-GlbA 
compound in complex with the proteasome and determined the X-ray structure. The electron 
density map displays covalent binding of the Thr-1Oγ of all active sites to the macrolactam ring 
of the ligand via ether bond formation, thus providing insights into the structure-activity 
relationship for the improved affinity of SylA-GlbA for the CT-L activity compared to the 
natural compounds SylA and GlbA. Our study revealed that the novel synthetic syrbactin 
compound represents one of the most potent proteasome inhibitors analyzed to date and therefore 
exhibits promising properties for an improved drug development as an anti-cancer therapeutic. 
 
 
 
Key words: cancer; co-crystallization; NF-κB; proteasome inhibitor; structure-activity 
relationship; syrbactin analog 
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INTRODUCTION 
Syrbactins are natural product small molecules that include the syringolins and glidobactins. 
While syringolins were identified more recently in isolates from the plant pathogen 
Pseudomonas syringae pv. syringae (Pss) (1), the structurally-related glidobactins were 
discovered in the 1980’s from an unknown species of the order Burkholderiales (2-5). Syringolin 
A (SylA) and glidobactin A (GlbA) represent the predominant forms in these bacterial 
pathogens, whereas SylB-F and GlbB-F are naturally occurring syrbactin variants expressed in 
minor quantities (1, 6, 7). 
In 2006, we demonstrated that the plant pathogen-derived natural product SylA induces 
massive p53 accumulation followed by apoptosis in neuroblastoma and ovarian cancer cells (8). 
Two years later, we discovered that SylA represents a bacterial virulence factor that irreversibly 
inhibits the eukaryotic proteasome by a novel mechanism (9). The proteasome is a multi-protein 
complex that is responsible for intracellular protein degradation, both via ubiquitin-dependent 
and ubiquitin-independent proteolysis (10-13). Many of these proteasome-controlled proteins 
regulate cell division, proliferation, and apoptosis and proteasome inhibitors represent a 
promising family of anti-neoplastic agents (12-19). Bortezomib (Velcade®) is the first 
proteasome inhibitor approved by the U.S. Food and Drug Administration (FDA) for the 
treatment of refractory and/or relapsed multiple myeloma (MM) and mantle cell lymphoma and 
preclinical studies have validated a number of next-generation proteasome inhibitors such as 
carfilzomib (PR-171), marizomib (NPI-0052), and MLN9708 (13).  
Despite its success on the market, bortezomib therapy has several disadvantages, including 
intravenous administration and multiple side-effects such as thrombocytopenia, neutropenia, and 
gastrointestinal disorders. Bortezomib also leads to severe but reversible neurodegenerative 
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effects and triggers nerve degeneration by exhibiting substantial off-target activity (12). 
Additional challenges are the increasing chemoresistance and patient relapse in response to 
proteasome inhibitors and one novel approach may be to target the immunoproteasome, a 
proteasomal variant found predominantly in cells of hematopoietic origin that differs from the 
constitutive proteasome found in most other cell types (20). Indeed, the recent elucidation of the 
immune- and constitutive proteasome crystal structures revealed important differences in 
substrate and inhibitor specificity (21), thus providing new insights into the structure-guided 
design of novel lead structures selective for the immunoproteasome and sub-catalytic proteasome 
activities. 
We previously showed that SylA inhibits the chymotrypsin-like (CT-L), trypsin-like (T-L), 
and caspase-like (C-L) sub-catalytic activities of the proteasome, while GlbA inhibits the CT-L 
and T-L, but not C-L sub-catalytic activities (9). In 2009, the chemical synthesis of syringolin A 
and syringolin B was achieved (22), which spurred the subsequent synthesis of novel syringolin- 
and glidobactin-inspired syrbactin analogs (23-27). Of those, SylA-LIP and TIR-203 represent 
two novel analogs with improved biological activities (24, 27). Most recently, we synthesized the 
hybrid molecule SylA-GlbA (Fig.1) consisting of a SylA macrocycle connected to the lipophilic 
GlbA side chain and demonstrated that the SylA or GlbA macrocycle moiety has critical 
influence on the β1 (C-L) subsite selectivity (28).  To further evaluate the potency of this novel 
syrbactin analog, we performed a biological characterization of SylA-GlbA and determined the 
complex structure of the ligand with the proteasome in order to gain additional insights into 
inherent structure-activity relationships. 
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EXPERIMENTAL PROCEDURES 
Synthesis and natural product isolation of syrbactins. The SylA-GlbA hybrid (SylA-GlbA) 
and synthetic SylA were synthesized as previously reported (22, 28, 29). GlbA was isolated from 
its biological source as described (1, 30, 31). All compounds were dissolved in sterile DMSO 
and frozen in aliquots at -20° C. At the beginning of each experiment, aliquots were thawed and 
diluted to the final concentration.  
 
Mammalian cell cultures and reagents. The following panel of chemosensitive and 
chemoresistant cancer cell lines was used in this study. The human neuroblastoma (NB) cell line 
SK-N-SH was obtained from the American Type Culture Collection (ATCC) (32). Multiple 
myeloma (MM) cell lines MM1.S and MM1.RL are sensitive and resistant to dexamethasone, 
respectively. U266 is an IL-6 producing cell line isolated from the peripheral blood of a male 
myeloma patient. All myeloma cells were provided by N. Krett (Northwestern University) (33). 
The human ovarian cancer cell line SKOV3, which is resistant to several cytotoxic drugs was 
available at the University of Hawaii Cancer Center (34, 35). Cells were seeded 18-24 hours 
before syrbactin or bortezomib treatments and analyzed after 24-72 hours. Human embryonic 
kidney 293/NF-κB-Luc cell line was designed for monitoring the activity of the NF-κB and was 
purchased from Panomics (Freemont, CA, USA). This cell line contains chromosomal 
integration of a luciferase reporter construct regulated by the NF-κB response element. 
Transcription factors can bind to the response element when stimulated by certain agents, 
allowing transcription of the luciferase gene. N-tosyl-L-phenylalanyl chloromethyl ketone 
(TPCK) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), (E)-3-(4-
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Methylphenylsulfonyl)-2-propenenenitrile (BAY-11) was purchased from Cayman Chemical 
(Ann Arbor, MI, USA). Bortezomib was purchased from LC Laboratories (Woburn, MA, USA). 
 
In vitro proteasome activity assay. In vitro proteasome inhibition assays were performed in 
96-well microtiter plates with human erythrocyte 20S proteasomes using the Assay Kit for Drug 
Discovery AK-740 (Biomol). Reactions were performed at 37 °C in 100 µl volumes containing a 
serial dilution of SylA-GlbA, 2 µg/ml 20S proteasome and 100 µM Suc-LLVY-AMC, Boc-LRR-
AMC or Z-LLE-AMC for assaying the chymotrypsin-like, trypsin-like and caspase-like activity, 
respectively, according to instructions of the manufacturer. Fluorescence was monitored with an 
MWGt Sirius HT plate reader (BIO-TEK® Instruments) equipped with 360 nm excitation and 
460 nm emission filters.  
 
In vivo proteasome activity assay. The cell culture-based in vivo proteasome-Glo activity 
assay was performed as previously described (9, 24). Clear-bottom, white-walled 96-well 
microtiter cell culture plates (Greiner Bio-One North America Inc., Monroe, NC, USA), were 
seeded with cells as indicated and treated with syrbactin or bortezomib. Proteasome inhibition 
was measured using the proteasome Glo™ reagent according to the manufacturer’s instructions 
(Promega, Madison, WI, USA). In brief, cancer cells were treated with SylA-GlbA, GlbA, SylA 
or bortezomib at different concentrations as indicated, and incubated for 2 hours. After 
incubation, cells were incubated for 15 min with 100 µl of proteasome Glo reagent, which 
permeabilizes cells and contains the bioluminescent substrates Suc-LLVY-aminoluciferin, Z-
nLPnLD-aminoluciferin, and Z-LRR-aminoluciferin to determine the chymotrypsin-like (CT-L), 
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caspase-like (C-L), and trypsin-like (T-L) activities, respectively. The luminescence was 
measured with a Dynex MLX luminometer. 
 
Cell proliferation assay. The CellTiter 96 Aqueous One solution Cell Proliferation Assay (2-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner 
salt; MTS) (Promega, San Luis Obispo, CA, USA) measures metabolic cell activity and was 
used to indirectly determine the viability of cells after 48 hours treatment with SylA-GlbA at 
indicated concentrations (0-1 µM) by measuring the absorbance at 492 nm using a Perkin Elmer 
HTS7000 Plus bioassay reader. The IC50 values in Table 1 were calculated by setting the lowest 
dose at 100%, using 3PL curve fitting in Prism from GraphPad Software, Inc (La Jolla, CA). 
NF-κB activity assay. The NF-κB activity assay was performed as previously described (36). 
Briefly, HEK293/NF-κB-Luc cells were seeded into sterile white-walled 96-well plates at 2 x 104 
cells per well in Dulbecco’s modified media with 10% FBS.  After growing cells for 48 hr to 
90% confluence, the medium was replaced with fresh medium containing tumor necrosis factor 
alpha (TNF-α) (final concentration 30 ng/ml) and cells were treated simultaneously for 6 hr with 
inhibitor compounds (SylA-GlbA, SylA, and GlbA) at various concentrations.  To avoid false-
positive responses, a cytotoxicity control experiment was included in parallel to ensure that the 
NF-κB activity changes within the 6 hr incubation period are not due to cell death (data not 
shown). Luciferase activity was determined with a luciferase kit from Promega (Madison, WI, 
USA) according to the manufacturer’s instructions. Following treatment, the cells were washed 
with phosphate-buffered saline and 50 µL of 1x Reporter lysis buffer was added before plates 
were placed in a -80° C freezer. The following day, the cells were thawed and assayed for 
luciferase activity with a LUMIstar Galaxy Luminometer (BMG Labtechnologies, Durham, NC, 
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USA). As a positive control, two NF-κB inhibitors were used: N-tosyl-L-phenylalanyl 
chloromethyl ketone (TPCK) and (E)-3-(4-Methylphenylsulfonyl)-2-propenenenitrile (BAY-11). 
Results were expressed as a percentage relative to control (TNFα-treated) samples, and dose–
response curves were constructed for the determination of IC50 values, which were generated 
from the results of eight serial dilutions of inhibitor compounds. Data represent the mean of two 
independent experiments, each performed in triplicate (n=6). 
 
Co-crystallization. Crystals of the 20S proteasome from S. cerevisiae were grown in hanging 
drops at 20° C as already has been described (37) and incubated for 48 hours with the chemical 
compound SylA-GlbA at 10 mM. The protein concentration used for crystallization was 45 
mg/ml in Tris-HCl (10 mM, pH 7.5) and EDTA (1 mM). The drops contained 1 µl of protein and 
1 µl of the reservoir solution, containing 20 mM of magnesium acetate, 100 mM of morpholino-
ethane-sulphonic acid (pH 6.9) and 10% of MPD. 
The space group belongs to P21 with cell dimensions of a = 135.9 Å, b = 298.8 Å, c = 145.3 
Å and β = 112.6° (see Table S1). Data to 2.8 Å for the proteasome:inhibitor-complex were 
collected using synchrotron radiation with λ = 1.0 Å at the X06SA-beamline in 
SLS/Villingen/Switzerland. Crystals were soaked in a cryoprotecting buffer (30% MPD, 20 mM 
of magnesium acetate, 100 mM of morpholino-ethane-sulfonic acid pH 6.9) and frozen in a 
stream of liquid nitrogen gas at 100 K (Oxford Cryo Systems). X-ray intensities were evaluated 
by using XDS program package (38). The anisotropy of diffraction was corrected by an overall 
anisotropic temperature factor by comparing observed and calculated structure amplitudes using 
the program CNS (39, 40). The electron density map was improved by averaging and back 
transforming the reflections 10 times over the twofold non-crystallographic symmetry axis using 
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the program package MAIN (41). Conventional crystallographic rigid body, positional and 
temperature factor refinements were carried out with CNS using the yeast 20S proteasome 
structure as starting model (42). Modelling experiments were performed with the program 
MAIN. Apart from the bound inhibitor molecules, structural changes were only noted in the 
specificity pockets. Temperature factor refinement indicates full occupancies of all inhibitor 
binding sites. The inhibitors have been omitted for phasing. The refined proteasome:SylA-GlbA-
complex structures revealed current crystallographic values of Rcryst = 0.212, Rfree = 0.237 (43) 
(Table S1). 
 
 
RESULTS 
SylA-GlbA inhibits all three catalytic activities of the proteasome. In an effort to generate 
more effective SylA analogs that exhibit higher potency, we recently synthesized a hybrid 
molecule that combines SylA with properties of GlbA (28). As shown in Fig. 1, the hybrid 
molecule SylA-GlbA is built up from the SylA macrocycle connected to the GlbA side chain. To 
determine the resulting inhibitory properties of this hybrid molecule, we employed an in vitro 
proteasome assay. In this assay, SylA-GlbA inhibited the chymotrypsin-like (CT-L) activity with 
an apparent Ki of 12.5 ±1.5 nM, the trypsin-like (T-L) with an apparent Ki of 136.9 ±12.4 nM, 
and the caspase-like (C-L) activity with an apparent Ki of 3.7 ± 1.2 µM, thereby demonstrating 
that the proteasome inhibitor SylA-GlbA is one of the most potent syrbactins reported to date.   
To corroborate the in vitro analysis, we tested the effectiveness of SylA-GlbA in a cell 
culture-based system that allows the detection of each sub-catalytic proteasome activity in vivo. 
As shown in Fig. 2, SylA-GlbA inhibited the CT-L, T-L, and C-L activities in a dose-dependent 
Page 9 of 33
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 10 
manner, in five cancer cell lines representing multiple myeloma (MM1.S, MM1.RL, U266), 
neuroblastoma (SK-N-SH), and ovarian cancer (SKOV3). The syrbactin GlbA inhibited the 
proteasomal activities in a similar fashion. SylA and bortezomib were included as controls and 
tested in two cell lines (SK-N-SH and SKOV3). While SylA showed an expected weaker 
response with highest inhibitory effects against the CT-L activity of the proteasome, the FDA-
approved proteasome inhibitor bortezomib (Velcade) strongly inhibited the three catalytic 
activities in these two cell lines, with highest potency against the CT-L activity. 
 
SylA-GlbA inhibits the proliferation of cancer cells more effectively than SylA. To examine 
the effect of SylA-GlbA-induced proteasome inhibition on cancer cell proliferation, we tested 
five cancer cell lines in the presence of increasing inhibitor concentrations (Fig. 3). The 
inhibitory effect of SylA-GlbA was most prominent in multiple myeloma MM1.S cells and 
equally potent in dexamethasone-resistant multiple myeloma MM1.RL cells. SylA-GlbA also 
decreased the cell viability of multiple myeloma U266 cells, ovarian cancer SKOV3 cells, and 
neuroblastoma SK-N-SH cells in a dose-dependent fashion. At concentrations of 0.1 µM or 
higher, cell growth inhibition was 100% in both multiple myeloma cell lines MM1.S and 
MM1.RL. The concentration at which cell growth is inhibited by 50% (IC50) was calculated 
(Table 1) and determined at 28 nM (MM1.S), 27 nM (MM1.RL), 45 nM (U266), 109 nM 
(SKOV3), and 321 nM (SK-N-SH). In contrast, the IC50 values previously reported for SylA are 
between 9 µM and 39 µM (depending on cancer cell line) (8, 24), thus confirming that the novel 
hybrid syrbactin SylA-GlbA exhibits significantly more potent (100- to 2,000-fold) anti-
proliferative activity than SylA.  
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Syrbactins inactivate TNF-α induced NF-κB activity. To determine whether NF-κB 
inactivation might be the underlying mechanism of proteasome inhibitor-induced cell death, 
three syrbactins (SylA-GlbA, SylA, and GlbA) were tested in a cell culture-based NF-κB 
transcription factor assay using stably transfected HEK293/NF-κB-Luc cells. As shown in Table 
2, the hybrid molecule SylA-GlbA strongly inhibited the TNF-α stimulated NF-κB activity and 
was more potent than SylA or GlbA. Of note, the IC50 value of SylA-GlbA (2.87 µM) was 
comparable with those of well-established NF-κB inhibitors TPCK (4.2 µM) and BAY-11 (2.6 
µM) which were included as controls. These results demonstrate for the first time that similar to 
bortezomib, syrbactin-promoted proteasome blockage results in the inhibition of NF-κB activity, 
which then leads to apoptosis as we previously demonstrated (8, 24). 
 
Crystal structure of SylA-GlbA with the yeast 20S proteasome. In comparison with the 
natural product SylA the synthetic SylA-GlbA analog revealed significantly decreased IC50 
values for all three proteolytically active sites of approximately three orders of magnitude. 
Hence, we performed crystal structure analysis of SylA-GlbA in complex with the yeast 
proteasome at 2.8 Å resolution (Rfree=24.4%) for characterizing the ligand at the molecular level 
in comparison to SylA and GlbA. The electron density map displays the macrolactam ring of the 
SylA-GlbA-ligand covalently bound to the Thr-1Oγ by formation of an irreversible ether bond 
formation (Fig. 4A,B). The oxyanion-hole is occupied by the carbonyl-oxygen of the reactive 
1,4-Michael head group of the ligand. The SylA-GlbA peptide moiety adopts the formation of an 
antiparallel β-sheet in the non-primed substrate binding channel as observed previously (44). 
Furthermore, in the case of the CT-L and TL-active site the peptide backbone is also stabilized 
by hydrogen bond formation with Asp114 located on the adjacent subunit either being β6 or β2, 
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respectively. Of note, this additional stabilization is absent in the substrate binding channel 
forming the C-L site and explains the reduced affinity of SylA, GlbA and SylA-GlbA for the 
latter. Substantial variations in the binding probability between the CT-L, T-L and C-L activities 
are caused by the molecular flexibility of the distinct specificity pockets in respect to entropic 
and enthalpic ligand stabilization, thus being a prime cause for the preference of the syrbactins to 
predominantly block the CT-L site.  
Interestingly, although the structural superposition of the macrolactom rings of SylA, GlbA 
and SylA-GlbA match almost perfectly (r.m.s.d. < 0.2 Å; Fig. 4C), there exist major differences 
in the binding affinity between SylA versus GlbA and SylA-GlbA. This discrepancy can be 
explained that: i) SylA harbors an isopropyl side chain in P4, which, however due to the presence 
of a urea-moiety between P3 and P4, is out of frame and therefore performs only impaired 
interactions with the S4 specificity pocket; ii) the N-terminal aliphatic fatty acid chains in GlbA 
and SylA-GlbA, which point towards the adjacent subunit β6 in the CT-L substrate binding 
channel, gets stabilized in an apolar pocket (Fig. 4A). Remarkably, although the lipophilic tails 
between GlbA and SylA-GlbA differ in their orientation (Fig. 4C), the in vitro IC50 values of the 
natural product and the SylA-GlbA compound are quite similar. Thus, the strong binding affinity 
of GlbA and SylA-GlbA compared to SylA can be explained by the presence of the aliphatic 
linker which is flexible in solution but is bound to hydrophobic patches of the central hydrolytic 
proteasomal chamber upon ligand docking to the proteolytic centre. As a result and in contrast to 
SylA, this additional stabilization of GlbA as well as SylA-GlbA at the active site vicinity 
increases the mean residence time of the ligands and therefore allows completion of the 
irreversible ether-bond formation with the Thr1Oγ.  
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DISCUSSION 
Natural products involved in plant-pathogen interactions can serve as an inspiring source for 
the identification of new bioactive entities as well as provide strategies on how to achieve small 
molecule manipulation of biological systems (45). Syrbactin is a subordinate term for the 
syringolin, glidobactin, and cepafungin natural product families and their grouping is based on 
their related molecular frameworks, similar biosynthesis pathways, and identical modes-of-
action, being irreversible proteasome inhibition (46). Syrbactins are now recognized as a new, 
and structurally distinct class of proteasome inhibitors (15), which prompted the design of 
synthetic syrbactin-inspired analogs (23-27). 
Our study demonstrates that the synthetic hybrid molecule SylA-GlbA is a potent proteasome 
inhibitor and inhibits the three sub-catalytic activities in a dose-dependent manner and at 
concentrations comparable with bortezomib. SylA-GlbA also substantially inhibits the 
proliferation of several cancer cell lines, with most potent effects in multiple myeloma. While 
proteasome inhibition is a validated strategy for therapy of multiple myeloma, relapse is common 
and often associated with chemoresistance. Therefore, the identification of novel compounds that 
overcome resistance to conventional drugs as well as nonspecific proteasome inhibitors is 
increasingly important (20). Intriguingly, the dexamethasone-sensitive (MM1.S) and 
dexamethasone-resistant (MM1.RL) multiple myeloma cell lines were both inhibited by SylA-
GlbA in the nanomolar range with IC50 values at 28 nM and 27 nM, respectively, suggesting that 
SylA-GlbA is equally effective in multiple myeloma cells that exhibit chemoresistance to a 
conventional drug. In contrast, the (wild type) SylA was significantly less potent in both multiple 
myeloma cell lines and cell treatments required about five-fold higher drug concentrations in 
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dexamethasone-resistant cells to achieve comparable growth inhibition (8.5 µM and 39.3 µM, 
respectively) (24).  
The NF-κB transcription factor plays an important role in tumorigenesis through induction of 
cell proliferation, suppression of apoptosis, metastasis, and induction of angiogenesis (47). 
Bortezomib inhibits NF-κB activity, the mechanism attributed to its antitumor actions, which led 
to its approval by the Food and Drug Administration (FDA) in 2003 for the treatment of multiple 
myeloma. Based on our findings, syrbactins inactivate TNF-α activated NF-κB in stably 
transfected HEK293/NF-κB-Luc cells at micromolear concentrations, with highest potency in 
multiple myeloma.  
Given the large number of substrates of the proteasome, it seems surprising that inhibition of 
NF-κB activity should be the only mechanism by which proteasome inhibitors exert their anti-
tumor effects. Indeed, other proteasome inhibitors including clasto-lactacystin do not lead to IκB 
accumulation in the cytoplasm and nuclear loss of NF-κB and therefore do not inhibit NF-κB 
activity (48, 49). Moreover, a paradigm shift was recently introduced proposing that NF-κB 
inhibition might be irrelevant to the effects of bortezomib in multiple myeloma cells and 
involves other signaling routes and proteasome-independent degradation of IκBα (50, 51). The 
possible activation of distinct and cell-type specific downstream cell signaling events in response 
to proteasome inhibition might also explain why SylA-GlbA treatments were most effective in 
multiple myeloma cells (Fig. 3), despite the fact that the inhibition of proteasomal activities by 
SylA-GlbA was similar in all five tested cell lines (Fig. 2). 
The structural evaluation of SylA, GlbA and SylA-GlbA suggests an improved binding 
probability starting from a charged and highly polar moiety adjacent to the macrolactam scaffold 
in SylA with impaired binding affinity and continuing with an enhanced decoration as well as 
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exploitation of the distant hydrophobic pocket by an aliphatic linker that eventually can further 
be optimized with maximum inhibition values for future syrbactin-derivatives.  Thus, the 
structural elucidation of the SylA-GlbA-complex and its comparison with SylA and GlbA 
facilitates novel innovations via fragment-based drug design strategies to discover new chemical 
entities as demonstrated by the aliphatic linker of either the natural product GlbA or its synthetic 
derivative SylA-GlbA.  
In summary, we have characterized the novel synthetic syrbactin analog SylA-GlbA that 
incorporates unique structural features of both SylA and GlbA, creating a hybrid molecule that 
exhibits enhanced biological activity over other syrbactin compounds and is comparable with 
well-studied proteasome inhibitors such as the FDA-approved bortezomib used in the clinic. It is 
tempting to speculate that syrbactins could similarly be developed into a drug for the treatment 
of multiple myeloma and likely other types of cancer. To achieve this, further development of 
next-generation syrbactin analogs will be important in an endeavor to create other clinically 
relevant proteasome inhibitors that may be used to achieve therapeutic synergisms or as 
replacement therapies for bortezomib-chemoresistant multiple myeloma and other forms of 
cancer (17). 
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FIGURE LEGENDS 
FIGURE 1: Chemical structures of SylA, GlbA, and the SylA-GlbA hybrid molecule.  
(A) Syringolin A (SylA) is a natural product produced by the plant pathogen Pseudomonas 
syringae pv. syringae (Pss) and acts as a moderately potent proteasome inhibitor. (B) 
Glidobactin A (GlbA) is a natural product proteasome inhibitor produced by an unknown species 
of the order Burkholderiales which is referred to as strain K481-B101 (ATCC 53080). (C) SylA-
GlbA is a synthetic hybrid of SylA and GlbA.  
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FIGURE 2: SylA-GlbA inhibits proteasomal activities of tumor cells in vivo. A panel of human 
tumor cell lines including human multiple myeloma cell lines MM1.S (blue circles), MM1.RL 
(orange squares), and U266 (purple circles), human ovarian cancer cell line SKOV3 (green 
diamonds), and human neuroblastoma cell line SK-N-SH (red squares) were treated individually 
over a period of 2 hours with SylA-GlbA at various drug concentrations (0-10 µM). The natural 
product wild type SylA and the FDA-approved proteasome inhibitor bortezomib (Velcade) were 
included as controls and tested in two cell lines (SK-N-SH, red squares and SKOV3, green 
diamonds). The inhibition of the chymotrypsin-like (CT-L), trypsin-like (T-L), and caspase-like 
(C-L) proteasome activity was determined by incubating treated cells with the bioluminescent 
substrates Suc-LLVY-aminoluciferin, Z-LRR-aminoluciferin, and Z-nLPnLD-aminoluciferin to 
measure the CT-L, T-L, and C-L proteasome activities, respectively. Data normalized to controls 
represent the mean of three independent experiments, and each experiment was performed in 
duplicate (n=6); bars, ± SD. The CT-L activity measurements for GlbA, SylA, and bortezomib 
have been previously reported (24).  
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FIGURE 3: SylA-GlbA inhibits proliferation of tumor cells. A panel of human tumor cell lines 
including human multiple myeloma cell lines MM1.S (blue circles), MM1.RL (orange squares), 
and U266 (purple circles), human ovarian cancer cell line SKOV3 (green diamonds), and human 
neuroblastoma cell line SK-N-SH (red squares) were treated individually over a period of 48 
hours with SylA-GlbA at various concentrations (0-1 µM). The viability of cells was determined 
by MTS assay. Data normalized to controls represent the mean of three independent 
experiments, and each experiment was performed in triplicate (n=9); bars, SEM. 
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 27 
FIGURE 4: Structural characterization of SylA-GlbA. (A) Stereoview of 2Fo - Fc electron density 
map (grey mesh, 1σ) for the CT-L substrate binding channel in complex with SylA-GlbA 
(colored in green) which has been omitted prior phase calculations. The backbone of subunits β5 
and β6 are presented in rose and grey coils, respectively; side chains involved in ligand 
stabilization are drawn in balls-and sticks-representation whereas hydrogen bonds are indicated 
by orange dashed lines. The lipophilic pocket stabilizing the aliphatic linker of SylA-GlbA is 
formed by Tyr-6, Pro94, Tyr96 and Pro115 from subunit β6. Note, amino acid numbering of side 
chain residues is according to Loewe et al. (52). (B) Surface charge distribution shown for the 
CT-L active site. Surface colors indicate positive and negative electrostatic potentials contoured 
from 50 kT/e (intense blue) to -50 kT/e (intense red). Thr1 is colored in white and the inhibitor 
SylA-GlbA highlighted in green according to 4A. (C) Structural superposition of SylA-GlbA 
(green), GlbA (grey) and SylA (dark grey) bound to CT-L site. Thr1 of subunit β5 is colored in 
black. The orientation is according to 4A.  
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Figure 1 
SylA  GlbA 
Hybrid SylA-GlbA (SylA-GlbA) 
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Figure 3 
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Table 1 Cell viability  
IC50 values (nM) 
Cell line Hybrid SylA-GlbA 
MM1.S 28 ± 10 
MM1.RL 27 ± 9 
U266 45 ± 6 
SKOV3 109 ± 111 
SK-N-SH 321 ± 161 
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Table 2 Syrbactins inactivate NF-κB activity 
Compound                        IC50 values (µM)* 
Hybrid SylA-GlbA 2.87 ± 1.32 
SylA 6.80 ± 2.00 
GlbA 15.46 ± 2.90 
TPCK (control 1) 4.2 ± 0.86 
BAY-11 (control 2) 2.6 ± 0.12 
*Dose-response curves based on eight serial dilutions of syrbactin 
compounds SylA-GlbA, SylA, and GlbA, and NFκB inhibitors TPCK and 
BAY-11 (positive controls) were used to determine the IC50 values. Two 
independent experiments were performed in triplicate assays (n=6).  
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